Ⅱ型膠原α1 N端前體肽抗體費(fèi)用 英文名稱  Anti-procollagen type IIA

中文名稱  Ⅱ型膠原α1 N端前體肽抗體費(fèi)用 

別    名 Collagen II N-terminal propeptide; Collagen II alpha 1; COL2A1; COL2A1 protein; collagen, type II, alpha 1; collagen alpha-1(II); type II collagen; alpha-1 type II collagen; alpha1 type II collagen; Col2a1; AOM; Cartilage collagen; COL11A3; Collagen alpha 1(II) chain precursor; Collagen II alpha 1 polypeptide; Collagen type II alpha 1 (primary osteoarthritis spondyloepiphyseal dysplasia congenital); MGC131516; SEDC; Collagen alpha-1(II) chain; Alpha-1 type II collagen; CO2A1_HUMAN.

產(chǎn)品屬性：

濃    度  1mg/1ml

規(guī) 格  0.2ml/200μg

抗體來源  Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Chicken, Dog, Pig, Cow, Rabbit, Sheep, Guinea Pig, Danio rerio

產(chǎn)品類型   一抗  

研究領(lǐng)域    神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 細(xì)胞粘附分子 細(xì)胞骨架

蛋白分子量  predicted molecular weight: 17/163kDa 

性    狀   Lyophilized or Liquid

免 疫 原  KLH conjugated synthetic peptide derived from human Collagen II alpha 1 N-terminal propeptide

亞    型  IgG

純化方法   affinity purified by Protein A

儲 存 液   Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

Ⅱ型膠原α1 N端前體肽抗體費(fèi)用 產(chǎn)品應(yīng)用   ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 Collagen type II is the most abundant protein of cartilage matrix. Two isoforms exist and collagen type IIA is involved in early development of cartilage in embryos. The collagen is produced from type II procollagen when two teloterminal propeptides are digested from the precursor and released into the circulation. Procollagen type II N-terminal propeptide is considered a marker of cartilage synthesis and the normal concentration in serum is approximately 30ng/mL.

Function : Type II collagen is specific for cartilaginous tissues. It is essential for the normal embryonic development of the skeleton, for linear growth and for the ability of cartilage to resist compressive forces.

Subunit : Homotrimers of alpha 1(II) chains.

Subcellular Location : Secreted, extracellular space, extracellular matrix.

Post-translational modifications : Probably 3-hydroxylated on prolines by LEPREL1 (By similarity). Proline residues at the third position of the tripeptide repeating unit (G-X-P) are hydroxylated in some or all of the chains. Proline residues at the second position of the tripeptide repeating unit (G-P-X) are hydroxylated in some of the chains.

The N-telopeptide is covalently linked to the helical COL2 region of alpha 1(IX), alpha 2(IX) and alpha 3(IX) chain. The C-telopeptide is covalently linked to an another site in the helical region of alpha 3(IX) COL2.

DISEASE : Defects in COL2A1 are the cause of spondyloepiphyseal dysplasia congenital type (SEDC) [MIM:183900]. This disorder is characterized by disproportionate short stature and pleiotropic involvement of the skeletal and ocular systems.

Defects in COL2A1 are the cause of spondyloepimetaphyseal dysplasia Strudwick type (SEMD-STR) [MIM:184250]. A bone disease characterized by disproportionate short stature from birth, with a very short trunk and shortened limbs, and skeletal abnormalities including lordosis, scoliosis, flattened vertebrae, pectus carinatum, coxa vara, clubfoot, and abnormal epiphyses or metaphyses. A distinctive radiographic feature is irregular sclerotic changes, described as dappled in the metaphyses of the long bones.

Defects in COL2A1 are the cause of achondrogenesis type 2 (ACG2) [MIM:200610]; also known as achondrogenesis-hypochondrogenesis type II. ACG2 is a disease characterized by the absence of ossification in the vertebral column, sacrum and pubic bones.

Defects in COL2A1 are the cause of Legg-Calve-Perthes disease (LCPD) [MIM:150600]; also known as Legg-Perthes disease or Perthes disease. LCPD is characterized by loss of circulation to the femoral head, resulting in avascular necrosis in a growing child. Clinical pictures of the disease vary, depending on the phase of disease progression through ischemia, revascularization, fracture and collapse, and repair and remodeling of the bone.

Defects in COL2A1 are the cause of Kniest dysplasia (KD) [MIM:156550]; also known as Kniest syndrome or metatropic dwarfism type II. KD is a moderately severe chondrodysplasia phenotype that results from mutations in the COL2A1 gene. Characteristics of the disorder include a short trunk and extremities, mid-face hypoplasia, cleft palate, myopia, retinal detachment, and hearing loss.

Defects in COL2A1 are a cause of primary avascular necrosis of femoral head (ANFH) [MIM:608805]; also known as ischemic necrosis of the femoral head or osteonecrosis of the femoral head. ANFH causes disability that often requires surgical intervention. Most cases are sporadic, but families in which there is an autosomal dominant inheritance of the disease have been identified. It has been estimated that 300,000 to 600,000 people in the United States have ANFH. Approximately 15,000 new cases of this common and disabling disorder are reported annually. The age at the onset is earlier than that for osteoarthritis. The diagnosis is typically made when patients are between the ages of 30 and 60 years. The clinical manifestations, such as pain on exertion, a limping gait, and a discrepancy in leg length, cause considerable disability. Moreover, nearly 10 percent of the 500,000 total-hip arthroplasties performed each year in the United States involve patients with ANFH. As a result, this disease creates a substantial socioeconomic cost as well as a burden for patients and their families.

Defects in COL2A1 are the cause of osteoarthritis with mild chondrodysplasia (OACD) [MIM:604864]. Osteoarthritis is a common disease that produces joint pain and stiffness together with radiologic evidence of progressive degeneration of joint cartilage. Some forms of osteoarthritis are secondary to events such as trauma, infections, metabolic disorders, or congenital or heritable conditions that deform the epiphyses or related structures. In most patients, however, there is no readily identifiable cause of osteoarthritis. Inheritance in a Mendelian dominant manner has been demonstrated in some families with primary generalized osteoarthritis. Reports demonstrate coinheritance of primary generalized osteoarthritis with specific alleles of the gene COL2A1, the precursor of the major protein of cartilage.

Defects in COL2A1 are the cause of platyspondylic lethal skeletal dysplasia Torrance type (PLSD-T) [MIM:151210]. Platyspondylic lethal skeletal dysplasias (PLSDs) are a heterogeneous group of chondrodysplasias characterized by severe platyspondyly and limb shortening. PLSD-T is characterized by varying platyspondyly, short ribs with anterior cupping, hypoplasia of the lower ilia with broad ischial and pubic bones, and shortening of the tubular bones with splayed and cupped metaphyses. Histology of the growth plate typically shows focal hypercellularity with slightly enlarged chondrocytes in the resting cartilage and relatively well-preserved columnar formation and ossification at the chondro-osseous junction. PLSD-T is generally a perinatally lethal disease, but a few long-term survivors have been reported.

Defects in COL2A1 are the cause of multiple epiphyseal dysplasia with myopia and conductive deafness (EDMMD) [MIM:132450]. Multiple epiphyseal dysplasia is a generalized skeletal dysplasia associated with significant morbidity. Joint pain, joint deformity, waddling gait, and short stature are the main clinical signs and symptoms. EDMMD is an autosomal dominant disorder characterized by epiphyseal dysplasia associated with progressive myopia, retinal thinning, crenated cataracts, conductive deafness.

Defects in COL2A1 are the cause of spondyloperipheral dysplasia (SPD) [MIM:271700]. SPD patients manifest short stature, midface hypoplasia, sensorineural hearing loss, spondyloepiphyseal dysplasia, platyspondyly and brachydactyly.

Similarity : Belongs to the fibrillar collagen family.

Contains 1 fibrillar collagen NC1 domain.

Contains 1 VWFC domain.

Database links : UniProtKB/Swiss-Prot: P02458.3

實(shí)驗流程：

全、新、優(yōu)、品、好四大特點(diǎn)：

Ⅱ型膠原α1 N端前體肽抗體費(fèi)用 全：公司提供上萬種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標(biāo)準(zhǔn)品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細(xì)胞等，基本上各種科研所需產(chǎn)品在我司都能找到。

新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。

優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。

好：我公司具有優(yōu)質(zhì)的技術(shù)團(tuán)隊，產(chǎn)品一旦售出，實(shí)驗過程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時沒有任何的后顧之憂。

正在熱銷的相關(guān)產(chǎn)品：

PDGF-BB(Human Platelet-Derived Growth Factor-BB) ELISA kit 人血小板衍生生長因子BBMulti-class antibodies規(guī)格： 48T

Anti-Gastrin 胃泌素/蛙皮素抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh Mouse Anti-human IgG(3D3)/Cy5.5 Cy5.5標(biāo)記的鼠抗人IgG單克隆抗體 規(guī)格 0.1ml

Human similar to RIKEN cDNA 2610307008 gene ELISA Kit 人類似RIKEN cDNA 2610307008 基因 96T

RNF150 英文名稱： 環(huán)指蛋白150抗體 0.2ml

Cdc23 英文名稱： 細(xì)胞分裂周期蛋白23抗體 0.2ml

Anti-Gastrin 胃泌素/蛙皮素抗體Multi-class antibodies規(guī)格： 0.1ml

Anti-Phospho-NMDAR2A (Tyr1325) /FITC 熒光素標(biāo)記磷酸化谷氨酸受體2A抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-CEA/HRP 辣根過氧化物酶標(biāo)記鼠抗人癌胚抗原單克隆抗體(檢測)IgGMulti-class antibodies規(guī)格： 0.2ml

CD167a抗體 Anti-CD167a/DDR1 0.1ml

Goat Anti-Mouse IgM/Gold 膠體金標(biāo)記的羊抗小鼠IgM 0.5ml

FK506 binding protein associated protein 英文名稱： FK506結(jié)合蛋白相關(guān)蛋白抗體(他克莫司相關(guān)蛋白) 0.2ml

Rhesus antibody Rh PMA/Prostate Mucin Antigen 粘蛋白抗原抗體 規(guī)格 0.2ml

Anti-CEA/HRP 辣根過氧化物酶標(biāo)記鼠抗人癌胚抗原單克隆抗體(檢測)IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-IKI3 family protein/FITC 熒光素標(biāo)記擬南芥IKI3抗體IgGMulti-class antibodies規(guī)格： 0.2ml

anti-pRb/p105-Rb /FITC 熒光素標(biāo)記磷酸化成視網(wǎng)膜細(xì)胞瘤蛋白抗體IgGMulti-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh AQP0/MIP26 水通道蛋白0抗體 規(guī)格 0.1ml

Rabbit anti-MG IgG/Cy3 Cy3標(biāo)記的兔抗長爪沙鼠IgG 0.1ml

GGNBP1 英文名稱： 配子生成素結(jié)合蛋白1抗體 0.2ml

Rhesus antibody Rh Rabbit Anti-Mink IgG/Alexa Fluor 555 Alexa Fluor 555標(biāo)記的兔抗水貂IgG 規(guī)格 0.1ml

anti-pRb/p105-Rb /FITC 熒光素標(biāo)記磷酸化成視網(wǎng)膜細(xì)胞瘤蛋白抗體IgGMulti-class antibodies規(guī)格： 0.1ml

大鼠巨噬細(xì)胞炎性蛋白3α(MIP-3α/CCL20)ELISA試劑盒 ，英文名： MIP-3α/CCL20 ELISA Kit

人凋亡相關(guān)因子配體(FASL)ELISA檢測試劑盒HumanFactor-relatedApoptosisligand,FASLELISAKit 96T/48T

病毒(CSFV)核酸檢測試劑盒(PCR-熒光探針法) 48T

CLIAKitforNKAELISAKit(Ret)大鼠神經(jīng)肽A規(guī)格：48T/96T

體液CMV(CYTOMEGALOVIRUS)病毒定量PCR擴(kuò)增檢測試劑盒20次

ELISAKitTCGF-Ⅲ人T細(xì)胞生長因子-Ⅲ規(guī)格：48T/96T

大鼠白介素1α(IL-1α)ELISA試劑盒 ，英文名： IL-1α ELISA Kit

Rabbit maix metalloproteinase 5 (MMP-5) ELISA Kit 兔子基質(zhì)金屬蛋白酶5(MMP-5)ELISA試劑盒

ELISA 小鼠白介素-17(mouse IL-17) 48T/96T 進(jìn)口分裝

CLIAKitforIL-3(HumanIerleukin3)ELISAKIT人白介素3規(guī)格：48T/96T

通用型雞馬立克氏病Marek’sdiseasevirus(MDV)試劑盒20次

ELISAKitypsin大鼠胰蛋白酶規(guī)格：48T/96T

Ⅱ型膠原α1 N端前體肽抗體費(fèi)用 大鼠不對稱二甲基精酸(ADMA)ELISA試劑盒 96T/48T 試劑盒 組裝/原裝

人免疫球蛋白E Fc段受體Ⅰ(FcεRⅠ)免疫試劑盒 Human Receptor Ⅰ for the Fc region of immunoglobulin E,FcεRⅠ ELISA Kit

MouseVascuoarendothelialcellgrowthfactorreceptor1,VEGFR-1/Flt1ELISAKit小鼠內(nèi)皮細(xì)胞生長因子受體1(VEGFR-1/Flt1)ELISA試劑盒規(guī)格：96T/48T

石蠟切片組織CASPASE-3蛋白表達(dá)NBT顯色光學(xué)顯微鏡檢測試劑盒10/20次

humanProstaglandinF,PG-FELISA試劑盒人素F(PGF)ELISA試劑盒規(guī)格：96T/48T

HumahymosinELISAKit人胸腺肽(Thymosin)ELISA試劑盒規(guī)格：96T/48T

技術(shù)外包服務(wù):

★Ⅱ型膠原α1 N端前體肽抗體費(fèi)用 分子生物學(xué)：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學(xué)：基因合成、引物合成、基因測序、載體構(gòu)建等

★蛋白工程：原核、哺乳動物蛋白表達(dá)系統(tǒng)等

★病毒包裝：腺病毒、慢病毒等

★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★細(xì)胞工程：細(xì)胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復(fù)、克隆形成)、細(xì)胞培養(yǎng)、細(xì)胞膜制備、穩(wěn)定細(xì)胞株構(gòu)建、細(xì)胞RNAi技術(shù)等等。